
Becton, Dickinson and Co.
BDXBecton, Dickinson and Co. (BDX) is a global medical technology company specializing in the development and manufacturing of medical devices, supplies, and laboratory equipment. Founded in 1897, it is known for its innovations in healthcare including syringes, safety-engineered devices, and diagnostic products, serving healthcare institutions, life sciences, and general medical markets worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2026 | $1.05 | 2026-06-09 | 2026-06-09 |
| March 31, 2026 | $1.05 | 2026-03-10 | 2026-03-10 |
| December 31, 2025 | $1.05 | 2025-12-08 | 2025-12-08 |
| September 30, 2025 | $1.04 | 2025-09-08 | 2025-09-08 |
| June 30, 2025 | $1.04 | 2025-06-09 | 2025-06-09 |
Dividends Summary
- Consistent Payer: Becton, Dickinson and Co. has rewarded shareholders with 91 dividend payments over the past 22 years.
- Total Returned Value: Investors who held BDX shares during this period received a total of $53.45 per share in dividend income.
- Latest Payout: The most recent dividend of $1.05/share was paid 18 days ago, on June 30, 2026.
- Yield & Schedule: BDX currently pays dividends quarterly with an annual yield of 2.65%.
- Dividend Growth: Since 2004, the dividend payout has grown by 600.0%, from $0.15 to $1.05.
- Dividend Reliability: BDX has maintained or increased its dividend for 91 consecutive payments.
Company News
While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medici...
The global bloodstream infection testing market is expected to grow at a CAGR of 4.80% through 2035, driven by rising sepsis cases, antimicrobial stewardship mandates, and adoption of rapid molecular diagnostics. North America leads the market, with the U.S. contributing 87.4% of regional revenues, while Asia Pacific shows the fastest growth. Key...
The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North Ame...
The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects...
The global wound irrigation systems market is projected to grow from USD 307.87 million in 2025 to USD 430.05 million by 2035, with a CAGR of 3.55%. Growth is driven by rising chronic wound prevalence, increased surgical volumes, and innovations in pulsatile lavage systems. North America leads with 40% market share, while Asia Pacific shows the f...






